NEW YORK (Reuters Health)—The COVID-19 pandemic has accelerated the expansion of telemedicine across the U.S., which has opened up access to doctor’s offices for families with limited resources. But at the same time, the health disparity gap could continue to widen unless safeguards are put into place, according to a pair of new editorials. “There…
IL-1-Beta Blockade May Slow OA Progression
NEW YORK (Reuters Health)—Interleukin (IL) 1 beta is a key player in the osteoarthritis (OA) inflammatory process and inhibiting it may help slow the disease process, according to an exploratory analysis of data from the CANTOS trial.1 CANTOS participants who were treated with the IL-1-beta inhibitor canakinumab had a significantly lower rate of total hip…
Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis
In a head-to-head study, ixekizumab was a more effective treatment for nail psoriasis than ustekinumab and resulted in greater skin clearance for patients with plaque psoriasis…
The ACR Expresses Strong Support for Dr. Anthony Fauci
The ACR, on behalf of its more than 7,700 members of the professional rheumatology community, wishes to express strong support for Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID), and his continued and close involvement in the work to address the nation’s response to the COVID-19 pandemic. During…
Tocilizumab Fails Late-Stage Trial for COVID-19
ZURICH (Reuters)—Roche’s attempt to retool its rheumatoid arthritis drug Actemra/RoActemra (tocilizumab) to treat patients hospitalized with severe COVID-19-related pneumonia has failed in a late-stage trial, the Swiss company said on July 29. Roche launched the 452-patient trial in March as it joined other pharmaceutical companies seeking to re-purpose existing medicines to fight the pandemic. The…
Insights into Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Recent research found inflammatory arthritis caused by immune checkpoint inhibitors (ICIs) may become a long-term disease, requiring rheumatology care and immunomodulatory treatment. Some patients experience active inflammatory arthritis years after ICI cessation…
Denosumab Dosing Delays Tied to Increased Fracture Risk
NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…
Lenabasum for Diffuse Cutaneous Systemic Sclerosis
In a new study, Spiera et al. assessed the safety and efficacy of lenabasum, a synthetic, orally administered agonist of cannabinoid receptor 2 that modulates the endocannabinoid system to activate the resolution phase of innate immune responses, in diffuse cutaneous systemic sclerosis…
How to Empower Lupus Patients Through Social Media & Online Resources
Social media connections, such as LupusChat and online resources from the ACR’s Lupus Initiative, are providing safe spaces and support for lupus patients during the COVID-19 pandemic…
ACR Updates COVID-19 Clinical Guidance for Adult Patients
Note: This article was updated July 21 to add recommendations on restarting biologics following COVID-19. On April 29, the ACR released Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID‐19 Pandemic and later updated the guidance for publication in Arthritis & Rheumatology. The recommendations address various treatment options and provide general…
- « Previous Page
- 1
- …
- 190
- 191
- 192
- 193
- 194
- …
- 816
- Next Page »